China pharma projects disrupted by Sino-US tensions
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 17 2025
0mins
Source: Yahoo Finance
Impact of U.S.-China Trade Tensions: Chinese drug research firms are adjusting their project plans and stockpiling supplies due to concerns over U.S. supply chain access and increased tariffs, leading to potential delays in clinical trials and higher costs for testing.
Shift in Testing Locations: Companies like WuXi Biologics are considering conducting tests on U.S. clinical samples domestically rather than sending them to China, which could further complicate operations and increase expenses amidst ongoing trade uncertainties.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
